Another example of how #biomarkers can rescue the pharma pipeline and support drug value– The story of Amgen’s MAb and Roche’s Avastin

Amgen had put aside the monoclonal antibody, rilotumumab, which was being developed for the treatment of gastric cancer and is an Ab for the hepatocyte growth factor (HGF). The experimental biologic was acquired in the Immunex purchase for $16 billion in cash and stork in 2001, but because of concerns in improvements in survival the project was put aside. The …